Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PharmAkea

- PMLiVE

Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug

About 100,000 people are living with the progressive condition in the US alone

- PMLiVE

Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech...

Avalere Health

- PMLiVE

Boehringer Ingelheim’s idiopathic pulmonary fibrosis treatment recommended by NICE

Patients will be eligible for the antifibrotic treatment earlier in the course of their disease

Mike Bushell presenting PMEA award to two Bedrock employees

Bedrock Healthcare Communications is proud to accept the PMEA for Agility in Pharma Market Excellence

Recognition for a bold and imaginative approach to an actionable clinical consensus for MS patients.

Bedrock Healthcare Communications

- PMLiVE

Boehringer Ingelheim enrols first patient in pulmonary fibrosis phase 3 trial

BI 1015550 reduced the rate of lung function decline in patients with IPF in a phase 2 trial

- PMLiVE

AbbVie to acquire DJS Antibodies in $255m cash deal

The agreement includes DJS-002, an experimental drug for idiopathic pulmonary fibrosis

- PMLiVE

The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia

With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20...

Avalere Health

Biotech Innovation in the Time of COVID-19

Chris Garabedian, CEO of Xontogeny, dives into biotech and digital health innovation, current industry gaps and obstacles, how to encourage biotech entrepreneurs, AI & machine learning, and much more!

Impetus Digital

- PMLiVE

Qureight announces world’s first digital biomarker for lung fibrosis will ‘transform’ clinical trials

The AI-based Lung8 imaging software picked up differences in response between patients who had an experimental drug compared with those who took a placebo

- PMLiVE

Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data

The potential new oral treatment showed a reduction in lung function decline

- PMLiVE

Fishawack Health appoints new CEO, Jonathan Koch

Koch will draw on his exceptional experience leading global, customer-centered organizations of scale to build a sustainable future for Fishawack Health.

Avalere Health

Steven Cohen at BOLDSCIENCE

BOLDSCIENCE welcomes Steven Cohen to its leadership team to expand its strategic communication consulting services into regulatory approvals

Medical communications agency BOLDSCIENCE has hired industry veteran Steven Cohen to lead a new division that will help pharmaceutical and biotech clients navigate the most critical challenges they face throughout...

BOLDSCIENCE

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links